Calidi Biotherapeutics, Inc. (CLDWW)

OTCMKTS · Delayed Price · Currency is USD · Warrants
0.0055
0.00 (0.00%)
May 21, 2025, 4:00 PM EDT
-86.25%
Market Cap 14.33M
Revenue (ttm) n/a
Net Income (ttm) -27.95M
Shares Out n/a
EPS (ttm) -5.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,300
Average Volume 1,250
Open 0.0055
Previous Close 0.0055
Day's Range 0.0055 - 0.0055
52-Week Range 0.0004 - 0.0400
Beta n/a
RSI 45.65
Earnings Date Mar 14, 2025

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, and Phase 1, dose-escalation clinical trial for NNV1 in patients with newly diagnosed high-grade gliomas; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, w... [Read more]

Industry Biological Products, Except Diagnostic Substances
Sector Healthcare
CEO Eric Poma
Employees 28
Stock Exchange OTCMKTS
Ticker Symbol CLDWW
Full Company Profile

News

There is no news available yet.